Literature DB >> 21741592

BCL6: a novel target for therapy of Ph+ B cell acute lymphoblastic leukemia.

Richard A Van Etten1.   

Abstract

BCL6 is a zinc-finger transcriptional repressor known for its oncogenic role in B cell lymphoma. In a recent issue of Nature, Duy et al. describe a novel role for BCL6 at the center of a transcriptional network in Ph(+) acute lymphoblastic leukemia cells that modulates their leukemogenicity and response to kinase inhibitors.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Year:  2011        PMID: 21741592     DOI: 10.1016/j.ccr.2011.06.021

Source DB:  PubMed          Journal:  Cancer Cell        ISSN: 1535-6108            Impact factor:   31.743


  2 in total

1.  Switching to BCL-6 Negativity in Relapsed Diffuse Large B Cell Lymphoma Correlated with More Aggressive Disease Course.

Authors:  Milena Todorović; Bela Balint; Bosko Andjelic; Ziv Radisavljevic; Biljana Mihaljevic
Journal:  Indian J Hematol Blood Transfus       Date:  2014-04-02       Impact factor: 0.900

Review 2.  Recent progress in targeting cancer.

Authors:  Zoya N Demidenko; James A McCubrey
Journal:  Aging (Albany NY)       Date:  2011-12       Impact factor: 5.682

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.